Oral PD-L1 inhibitor GS-4224 selectively engages PD-L1 high cells and elicits pharmacodynamic responses in patients with advanced solid tumors

Background Checkpoint inhibitors targeting the programmed cell death 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) pathway are effective therapies in a range of immunogenic cancer types. Blocking this pathway with an oral therapy could benefit patients through greater convenience, particularly i...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Nicholas Waldron, P Rod Dunbar, Sanjeev Deva, Oh Kyu Yoon, John Ling, Kai-Wen Lin, Dung Thai, Latesh Lad, Ahmed A Othman, Jared M Odegard, Adele Y Wang, Jonathan Nazareno, Edmond Ang
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	BMJ Publishing Group 2024-04-01
סדרה:	Journal for ImmunoTherapy of Cancer
גישה מקוונת:	https://jitc.bmj.com/content/12/4/e008547.full
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!